APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Janus Kinase Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Research

Cancer Janus Kinase Inhibitors Industry Research Report 2026

22 December 2025134 pages

Choose your research edition.

Industry ResearchCancer Janus Kinase Inhibitors Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Janus Kinase Inhibitors Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Cancer Janus Kinase Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Janus Kinase Inhibitors Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Janus Kinase Inhibitors Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Cancer Janus Kinase Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Cancer Janus Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Cancer Janus Kinase Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Cancer Janus Kinase Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Cancer Janus Kinase Inhibitors include Eli Lilly, Gilead Sciences, Pfizer, S-BIO, Portola Pharmaceuticals, PIQUR Therapeutics, Moleculin, Kyowa Hakko and Incyte, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Cancer Janus Kinase Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Cancer Janus Kinase Inhibitors Market by Company

Eli Lilly

Gilead Sciences

Pfizer

S-BIO

Portola Pharmaceuticals

PIQUR Therapeutics

Moleculin

Kyowa Hakko

Incyte

Hanmi Pharmaceuticals

Dynamic Pharma

Celon Pharmaceuticals

Astra Zeneca

Asana Biosciences

Abbott Laboratories

Cancer Janus Kinase Inhibitors Segment by Type

Pacritinib

Momelotinib

Ruxolitinib

Lestaurtinib

Cancer Janus Kinase Inhibitors Segment by Application

Hospitals

Ambulatory Surgical Centers

Others

Cancer Janus Kinase Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Janus Kinase Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Janus Kinase Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Janus Kinase Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Cancer Janus Kinase Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Cancer Janus Kinase Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Cancer Janus Kinase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Cancer Janus Kinase Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Cancer Janus Kinase Inhibitors Sales (k units) of Manufacturers (2021-2026) Table 7. Global Cancer Janus Kinase Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 8. Global Cancer Janus Kinase Inhibitors Revenue of Manufacturers (2021-2026) Table 9. Global Cancer Janus Kinase Inhibitors Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Cancer Janus Kinase Inhibitors Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Cancer Janus Kinase Inhibitors Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Cancer Janus Kinase Inhibitors, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Cancer Janus Kinase Inhibitors, Product Type & Application Table 14. Global Cancer Janus Kinase Inhibitors Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Cancer Janus Kinase Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Eli Lilly Company Information Table 19. Eli Lilly Business Overview Table 20. Eli Lilly Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Eli Lilly Cancer Janus Kinase Inhibitors Product Portfolio Table 22. Eli Lilly Recent Developments Table 23. Gilead Sciences Company Information Table 24. Gilead Sciences Business Overview Table 25. Gilead Sciences Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Gilead Sciences Cancer Janus Kinase Inhibitors Product Portfolio Table 27. Gilead Sciences Recent Developments Table 28. Pfizer Company Information Table 29. Pfizer Business Overview Table 30. Pfizer Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Pfizer Cancer Janus Kinase Inhibitors Product Portfolio Table 32. Pfizer Recent Developments Table 33. S-BIO Company Information Table 34. S-BIO Business Overview Table 35. S-BIO Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. S-BIO Cancer Janus Kinase Inhibitors Product Portfolio Table 37. S-BIO Recent Developments Table 38. Portola Pharmaceuticals Company Information Table 39. Portola Pharmaceuticals Business Overview Table 40. Portola Pharmaceuticals Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Portola Pharmaceuticals Cancer Janus Kinase Inhibitors Product Portfolio Table 42. Portola Pharmaceuticals Recent Developments Table 43. PIQUR Therapeutics Company Information Table 44. PIQUR Therapeutics Business Overview Table 45. PIQUR Therapeutics Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. PIQUR Therapeutics Cancer Janus Kinase Inhibitors Product Portfolio Table 47. PIQUR Therapeutics Recent Developments Table 48. Moleculin Company Information Table 49. Moleculin Business Overview Table 50. Moleculin Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Moleculin Cancer Janus Kinase Inhibitors Product Portfolio Table 52. Moleculin Recent Developments Table 53. Kyowa Hakko Company Information Table 54. Kyowa Hakko Business Overview Table 55. Kyowa Hakko Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Kyowa Hakko Cancer Janus Kinase Inhibitors Product Portfolio Table 57. Kyowa Hakko Recent Developments Table 58. Incyte Company Information Table 59. Incyte Business Overview Table 60. Incyte Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Incyte Cancer Janus Kinase Inhibitors Product Portfolio Table 62. Incyte Recent Developments Table 63. Hanmi Pharmaceuticals Company Information Table 64. Hanmi Pharmaceuticals Business Overview Table 65. Hanmi Pharmaceuticals Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Hanmi Pharmaceuticals Cancer Janus Kinase Inhibitors Product Portfolio Table 67. Hanmi Pharmaceuticals Recent Developments Table 68. Dynamic Pharma Company Information Table 69. Dynamic Pharma Business Overview Table 70. Dynamic Pharma Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Dynamic Pharma Cancer Janus Kinase Inhibitors Product Portfolio Table 72. Dynamic Pharma Recent Developments Table 73. Celon Pharmaceuticals Company Information Table 74. Celon Pharmaceuticals Business Overview Table 75. Celon Pharmaceuticals Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Celon Pharmaceuticals Cancer Janus Kinase Inhibitors Product Portfolio Table 77. Celon Pharmaceuticals Recent Developments Table 78. Astra Zeneca Company Information Table 79. Astra Zeneca Business Overview Table 80. Astra Zeneca Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Astra Zeneca Cancer Janus Kinase Inhibitors Product Portfolio Table 82. Astra Zeneca Recent Developments Table 83. Asana Biosciences Company Information Table 84. Asana Biosciences Business Overview Table 85. Asana Biosciences Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Asana Biosciences Cancer Janus Kinase Inhibitors Product Portfolio Table 87. Asana Biosciences Recent Developments Table 88. Abbott Laboratories Company Information Table 89. Abbott Laboratories Business Overview Table 90. Abbott Laboratories Cancer Janus Kinase Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Abbott Laboratories Cancer Janus Kinase Inhibitors Product Portfolio Table 92. Abbott Laboratories Recent Developments Table 93. Global Cancer Janus Kinase Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Cancer Janus Kinase Inhibitors Sales by Region (2021-2026) & (k units) Table 95. Global Cancer Janus Kinase Inhibitors Sales Market Share by Region (2021-2026) Table 96. Global Cancer Janus Kinase Inhibitors Sales by Region (2027-2032) & (k units) Table 97. Global Cancer Janus Kinase Inhibitors Sales Market Share by Region (2027-2032) Table 98. Global Cancer Janus Kinase Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Region (2021-2026) Table 100. Global Cancer Janus Kinase Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Region (2027-2032) Table 102. North America Cancer Janus Kinase Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Cancer Janus Kinase Inhibitors Sales by Country (2021-2026) & (k units) Table 104. North America Cancer Janus Kinase Inhibitors Sales by Country (2027-2032) & (k units) Table 105. North America Cancer Janus Kinase Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Cancer Janus Kinase Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Cancer Janus Kinase Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Cancer Janus Kinase Inhibitors Sales by Country (2021-2026) & (k units) Table 109. Europe Cancer Janus Kinase Inhibitors Sales by Country (2027-2032) & (k units) Table 110. Europe Cancer Janus Kinase Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Cancer Janus Kinase Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Cancer Janus Kinase Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Cancer Janus Kinase Inhibitors Sales by Country (2021-2026) & (k units) Table 114. Asia Pacific Cancer Janus Kinase Inhibitors Sales by Country (2027-2032) & (k units) Table 115. Asia Pacific Cancer Janus Kinase Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Cancer Janus Kinase Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Cancer Janus Kinase Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Cancer Janus Kinase Inhibitors Sales by Country (2021-2026) & (k units) Table 119. South America Cancer Janus Kinase Inhibitors Sales by Country (2027-2032) & (k units) Table 120. South America Cancer Janus Kinase Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Cancer Janus Kinase Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Cancer Janus Kinase Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Cancer Janus Kinase Inhibitors Sales by Country (2021-2026) & (k units) Table 124. Middle East and Africa Cancer Janus Kinase Inhibitors Sales by Country (2027-2032) & (k units) Table 125. Middle East and Africa Cancer Janus Kinase Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Cancer Janus Kinase Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Cancer Janus Kinase Inhibitors Sales by Type (2021-2026) & (k units) Table 128. Global Cancer Janus Kinase Inhibitors Sales by Type (2027-2032) & (k units) Table 129. Global Cancer Janus Kinase Inhibitors Sales Market Share by Type (2021-2026) Table 130. Global Cancer Janus Kinase Inhibitors Sales Market Share by Type (2027-2032) Table 131. Global Cancer Janus Kinase Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Cancer Janus Kinase Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Type (2021-2026) Table 134. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Type (2027-2032) Table 135. Global Cancer Janus Kinase Inhibitors Price by Type (2021-2026) & (US$/unit) Table 136. Global Cancer Janus Kinase Inhibitors Price by Type (2027-2032) & (US$/unit) Table 137. Global Cancer Janus Kinase Inhibitors Sales by Application (2021-2026) & (k units) Table 138. Global Cancer Janus Kinase Inhibitors Sales by Application (2027-2032) & (k units) Table 139. Global Cancer Janus Kinase Inhibitors Sales Market Share by Application (2021-2026) Table 140. Global Cancer Janus Kinase Inhibitors Sales Market Share by Application (2027-2032) Table 141. Global Cancer Janus Kinase Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Cancer Janus Kinase Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Application (2021-2026) Table 144. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Application (2027-2032) Table 145. Global Cancer Janus Kinase Inhibitors Price by Application (2021-2026) & (US$/unit) Table 146. Global Cancer Janus Kinase Inhibitors Price by Application (2027-2032) & (US$/unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Cancer Janus Kinase Inhibitors Distributors List Table 150. Cancer Janus Kinase Inhibitors Customers List Table 151. Cancer Janus Kinase Inhibitors Industry Trends Table 152. Cancer Janus Kinase Inhibitors Industry Drivers Table 153. Cancer Janus Kinase Inhibitors Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Cancer Janus Kinase Inhibitors Product Image Figure 5. Global Cancer Janus Kinase Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Cancer Janus Kinase Inhibitors Market Size (2021-2032) & (US$ Million) Figure 7. Global Cancer Janus Kinase Inhibitors Sales (2021-2032) & (k units) Figure 8. Global Cancer Janus Kinase Inhibitors Average Price (US$/unit) & (2021-2032) Figure 9. Pacritinib Product Image Figure 10. Momelotinib Product Image Figure 11. Ruxolitinib Product Image Figure 12. Lestaurtinib Product Image Figure 13. Hospitals Product Image Figure 14. Ambulatory Surgical Centers Product Image Figure 15. Others Product Image Figure 16. Global Cancer Janus Kinase Inhibitors Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Cancer Janus Kinase Inhibitors, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Cancer Janus Kinase Inhibitors Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Cancer Janus Kinase Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Cancer Janus Kinase Inhibitors Sales by Region in 2025 Figure 22. Global Cancer Janus Kinase Inhibitors Revenue by Region in 2025 Figure 23. North America Cancer Janus Kinase Inhibitors Market Size by Country in 2025 Figure 24. North America Cancer Janus Kinase Inhibitors Sales Market Share by Country (2021-2032) Figure 25. North America Cancer Janus Kinase Inhibitors Revenue Market Share by Country (2021-2032) Figure 26. United States Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Cancer Janus Kinase Inhibitors Market Size by Country in 2025 Figure 30. Europe Cancer Janus Kinase Inhibitors Sales Market Share by Country (2021-2032) Figure 31. Europe Cancer Janus Kinase Inhibitors Revenue Market Share by Country (2021-2032) Figure 32. Germany Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Cancer Janus Kinase Inhibitors Market Size by Country in 2025 Figure 43. Asia Pacific Cancer Janus Kinase Inhibitors Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Cancer Janus Kinase Inhibitors Revenue Market Share by Country (2021-2032) Figure 45. China Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Cancer Janus Kinase Inhibitors Market Size by Country in 2025 Figure 54. South America Cancer Janus Kinase Inhibitors Sales Market Share by Country (2021-2032) Figure 55. South America Cancer Janus Kinase Inhibitors Revenue Market Share by Country (2021-2032) Figure 56. Brazil Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Cancer Janus Kinase Inhibitors Market Size by Country in 2025 Figure 60. Middle East and Africa Cancer Janus Kinase Inhibitors Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Cancer Janus Kinase Inhibitors Revenue Market Share by Country (2021-2032) Figure 62. Egypt Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Cancer Janus Kinase Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Cancer Janus Kinase Inhibitors Sales Market Share by Type (2021-2032) Figure 68. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Type (2021-2032) Figure 69. Global Cancer Janus Kinase Inhibitors Price (US$/unit) by Type (2021-2032) Figure 70. Global Cancer Janus Kinase Inhibitors Sales Market Share by Application (2021-2032) Figure 71. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Application (2021-2032) Figure 72. Global Cancer Janus Kinase Inhibitors Price (US$/unit) by Application (2021-2032) Figure 73. Cancer Janus Kinase Inhibitors Value Chain Figure 74. Cancer Janus Kinase Inhibitors Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Cancer Janus Kinase Inhibitors Industry Opportunities and Challenges

Scope & coverage.

Types
  • Pacritinib
  • Momelotinib
  • Ruxolitinib
  • Lestaurtinib
Applications
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
Companies covered
  • Eli Lilly
  • Gilead Sciences
  • Pfizer
  • S-BIO
  • Portola Pharmaceuticals
  • PIQUR Therapeutics
  • Moleculin
  • Kyowa Hakko
  • Incyte
  • Hanmi Pharmaceuticals
  • Dynamic Pharma
  • Celon Pharmaceuticals
  • Astra Zeneca
  • Asana Biosciences
  • Abbott Laboratories

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Cancer Janus Kinase Inhibitors Market Size (2021-2032)
  4. 2.2.2 Global Cancer Janus Kinase Inhibitors Sales (2021-2032)
  5. 2.2.3 Global Cancer Janus Kinase Inhibitors Market Average Price (2021-2032)
  6. 2.3 Cancer Janus Kinase Inhibitors by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Pacritinib
  9. 2.3.3 Momelotinib
  10. 2.3.4 Ruxolitinib
  11. 2.3.5 Lestaurtinib
  12. 2.4 Cancer Janus Kinase Inhibitors by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Hospitals
  15. 2.4.3 Ambulatory Surgical Centers
  16. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Cancer Janus Kinase Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Cancer Janus Kinase Inhibitors Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Cancer Janus Kinase Inhibitors Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Cancer Janus Kinase Inhibitors Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Cancer Janus Kinase Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Cancer Janus Kinase Inhibitors, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Cancer Janus Kinase Inhibitors, Product Type & Application
  8. 3.8 Global Manufacturers of Cancer Janus Kinase Inhibitors, Established Date
  9. 3.9 Global Cancer Janus Kinase Inhibitors Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Eli Lilly
  2. 4.1.1 Eli Lilly Company Information
  3. 4.1.2 Eli Lilly Business Overview
  4. 4.1.3 Eli Lilly Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Eli Lilly Cancer Janus Kinase Inhibitors Product Portfolio
  6. 4.1.5 Eli Lilly Recent Developments
  7. 4.2 Gilead Sciences
  8. 4.2.1 Gilead Sciences Company Information
  9. 4.2.2 Gilead Sciences Business Overview
  10. 4.2.3 Gilead Sciences Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Gilead Sciences Cancer Janus Kinase Inhibitors Product Portfolio
  12. 4.2.5 Gilead Sciences Recent Developments
  13. 4.3 Pfizer
  14. 4.3.1 Pfizer Company Information
  15. 4.3.2 Pfizer Business Overview
  16. 4.3.3 Pfizer Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Pfizer Cancer Janus Kinase Inhibitors Product Portfolio
  18. 4.3.5 Pfizer Recent Developments
  19. 4.4 S-BIO
  20. 4.4.1 S-BIO Company Information
  21. 4.4.2 S-BIO Business Overview
  22. 4.4.3 S-BIO Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 S-BIO Cancer Janus Kinase Inhibitors Product Portfolio
  24. 4.4.5 S-BIO Recent Developments
  25. 4.5 Portola Pharmaceuticals
  26. 4.5.1 Portola Pharmaceuticals Company Information
  27. 4.5.2 Portola Pharmaceuticals Business Overview
  28. 4.5.3 Portola Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Portola Pharmaceuticals Cancer Janus Kinase Inhibitors Product Portfolio
  30. 4.5.5 Portola Pharmaceuticals Recent Developments
  31. 4.6 PIQUR Therapeutics
  32. 4.6.1 PIQUR Therapeutics Company Information
  33. 4.6.2 PIQUR Therapeutics Business Overview
  34. 4.6.3 PIQUR Therapeutics Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 PIQUR Therapeutics Cancer Janus Kinase Inhibitors Product Portfolio
  36. 4.6.5 PIQUR Therapeutics Recent Developments
  37. 4.7 Moleculin
  38. 4.7.1 Moleculin Company Information
  39. 4.7.2 Moleculin Business Overview
  40. 4.7.3 Moleculin Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Moleculin Cancer Janus Kinase Inhibitors Product Portfolio
  42. 4.7.5 Moleculin Recent Developments
  43. 4.8 Kyowa Hakko
  44. 4.8.1 Kyowa Hakko Company Information
  45. 4.8.2 Kyowa Hakko Business Overview
  46. 4.8.3 Kyowa Hakko Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Kyowa Hakko Cancer Janus Kinase Inhibitors Product Portfolio
  48. 4.8.5 Kyowa Hakko Recent Developments
  49. 4.9 Incyte
  50. 4.9.1 Incyte Company Information
  51. 4.9.2 Incyte Business Overview
  52. 4.9.3 Incyte Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Incyte Cancer Janus Kinase Inhibitors Product Portfolio
  54. 4.9.5 Incyte Recent Developments
  55. 4.10 Hanmi Pharmaceuticals
  56. 4.10.1 Hanmi Pharmaceuticals Company Information
  57. 4.10.2 Hanmi Pharmaceuticals Business Overview
  58. 4.10.3 Hanmi Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Hanmi Pharmaceuticals Cancer Janus Kinase Inhibitors Product Portfolio
  60. 4.10.5 Hanmi Pharmaceuticals Recent Developments
  61. 4.11 Dynamic Pharma
  62. 4.11.1 Dynamic Pharma Company Information
  63. 4.11.2 Dynamic Pharma Business Overview
  64. 4.11.3 Dynamic Pharma Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Dynamic Pharma Cancer Janus Kinase Inhibitors Product Portfolio
  66. 4.11.5 Dynamic Pharma Recent Developments
  67. 4.12 Celon Pharmaceuticals
  68. 4.12.1 Celon Pharmaceuticals Company Information
  69. 4.12.2 Celon Pharmaceuticals Business Overview
  70. 4.12.3 Celon Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Celon Pharmaceuticals Cancer Janus Kinase Inhibitors Product Portfolio
  72. 4.12.5 Celon Pharmaceuticals Recent Developments
  73. 4.13 Astra Zeneca
  74. 4.13.1 Astra Zeneca Company Information
  75. 4.13.2 Astra Zeneca Business Overview
  76. 4.13.3 Astra Zeneca Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Astra Zeneca Cancer Janus Kinase Inhibitors Product Portfolio
  78. 4.13.5 Astra Zeneca Recent Developments
  79. 4.14 Asana Biosciences
  80. 4.14.1 Asana Biosciences Company Information
  81. 4.14.2 Asana Biosciences Business Overview
  82. 4.14.3 Asana Biosciences Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Asana Biosciences Cancer Janus Kinase Inhibitors Product Portfolio
  84. 4.14.5 Asana Biosciences Recent Developments
  85. 4.15 Abbott Laboratories
  86. 4.15.1 Abbott Laboratories Company Information
  87. 4.15.2 Abbott Laboratories Business Overview
  88. 4.15.3 Abbott Laboratories Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Abbott Laboratories Cancer Janus Kinase Inhibitors Product Portfolio
  90. 4.15.5 Abbott Laboratories Recent Developments
5 Global Cancer Janus Kinase Inhibitors Market Scenario by Region
  1. 5.1 Global Cancer Janus Kinase Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Cancer Janus Kinase Inhibitors Sales by Region: 2021-2032
  3. 5.2.1 Global Cancer Janus Kinase Inhibitors Sales by Region: 2021-2026
  4. 5.2.2 Global Cancer Janus Kinase Inhibitors Sales by Region: 2027-2032
  5. 5.3 Global Cancer Janus Kinase Inhibitors Revenue by Region: 2021-2032
  6. 5.3.1 Global Cancer Janus Kinase Inhibitors Revenue by Region: 2021-2026
  7. 5.3.2 Global Cancer Janus Kinase Inhibitors Revenue by Region: 2027-2032
  8. 5.4 North America Cancer Janus Kinase Inhibitors Market Facts & Figures by Country
  9. 5.4.1 North America Cancer Janus Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Cancer Janus Kinase Inhibitors Sales by Country (2021-2032)
  11. 5.4.3 North America Cancer Janus Kinase Inhibitors Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Cancer Janus Kinase Inhibitors Market Facts & Figures by Country
  16. 5.5.1 Europe Cancer Janus Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Cancer Janus Kinase Inhibitors Sales by Country (2021-2032)
  18. 5.5.3 Europe Cancer Janus Kinase Inhibitors Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Cancer Janus Kinase Inhibitors Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Cancer Janus Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Cancer Janus Kinase Inhibitors Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Cancer Janus Kinase Inhibitors Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Cancer Janus Kinase Inhibitors Market Facts & Figures by Country
  41. 5.7.1 South America Cancer Janus Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Cancer Janus Kinase Inhibitors Sales by Country (2021-2032)
  43. 5.7.3 South America Cancer Janus Kinase Inhibitors Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Cancer Janus Kinase Inhibitors Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Cancer Janus Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Cancer Janus Kinase Inhibitors Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Cancer Janus Kinase Inhibitors Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Cancer Janus Kinase Inhibitors Sales by Type (2021-2032)
  2. 6.1.1 Global Cancer Janus Kinase Inhibitors Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Cancer Janus Kinase Inhibitors Sales Market Share by Type (2021-2032)
  4. 6.2 Global Cancer Janus Kinase Inhibitors Revenue by Type (2021-2032)
  5. 6.2.1 Global Cancer Janus Kinase Inhibitors Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Cancer Janus Kinase Inhibitors Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Cancer Janus Kinase Inhibitors Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Cancer Janus Kinase Inhibitors Sales by Application (2021-2032)
  2. 7.1.1 Global Cancer Janus Kinase Inhibitors Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Cancer Janus Kinase Inhibitors Sales Market Share by Application (2021-2032)
  4. 7.2 Global Cancer Janus Kinase Inhibitors Revenue by Application (2021-2032)
  5. 7.2.1 Global Cancer Janus Kinase Inhibitors Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Cancer Janus Kinase Inhibitors Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Cancer Janus Kinase Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Cancer Janus Kinase Inhibitors Value Chain Analysis
  2. 8.1.1 Cancer Janus Kinase Inhibitors Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Cancer Janus Kinase Inhibitors Production Mode & Process
  5. 8.2 Cancer Janus Kinase Inhibitors Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Cancer Janus Kinase Inhibitors Distributors
  8. 8.2.3 Cancer Janus Kinase Inhibitors Customers
9 Global Cancer Janus Kinase Inhibitors Analyzing Market Dynamics
  1. 9.1 Cancer Janus Kinase Inhibitors Industry Trends
  2. 9.2 Cancer Janus Kinase Inhibitors Industry Drivers
  3. 9.3 Cancer Janus Kinase Inhibitors Industry Opportunities and Challenges
  4. 9.4 Cancer Janus Kinase Inhibitors Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst